Dr. Xiaohu Fan, founder of Wondercel Therapeutics, is a globally recognized leader in the field of cellular immunotherapy. In July 2014, Dr. Fan returned to China and established Nanjing Legend Biotech in early 2015. He assembled a world-class R&D team and developed multiple cutting-edge CAR-T technology platforms. In 2017, Dr. Fan invented ciltacabtagene autoleucel (cilta-cel), a CAR-T product for the treatment of multiple myeloma. This was the world’s first CAR construct targeting BCMA with a dual-epitope binding domain, delivering groundbreaking clinical efficacy. The product received the first “Breakthrough Therapy Designation” in the history of Chinese medicine in August 2020, marking a transformative milestone for China’s CAR-T industry. It is currently the only Chinese original innovative cell therapy product that has successfully expanded overseas. Approved in the United States, European Union, Japan, and other regions under the brand name CARVYKTI®, the therapy is priced at $465,000 per dose. This success propelled Legend Biotech to become the global leader in the cell therapy industry with a market capitalization exceeding 100 billion RMB. Dr. Fan has also been recognized by the internationally renowned pharmaceutical media Endpoints News as one of the “Top 20 Most Influential Drug Developers in the World.”